|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:collaboratesWith
|
gptkb:UK_Research_and_Innovation
gptkb:Wellcome_Trust
NHS
|
|
gptkbp:country
|
gptkb:United_Kingdom
|
|
gptkbp:enrollment
|
over 47,000 participants
|
|
gptkbp:focus
|
gptkb:COVID-19
|
|
gptkbp:fullName
|
Randomised Evaluation of COVID-19 Therapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
RECOVERY Trial
|
|
gptkbp:impact
|
influenced global COVID-19 treatment guidelines
|
|
gptkbp:location
|
over 175 NHS hospitals in the UK
|
|
gptkbp:notableAchievement
|
Tocilizumab reduces mortality in some COVID-19 patients
Azithromycin found ineffective for COVID-19
Dexamethasone reduces mortality in severe COVID-19
Hydroxychloroquine found ineffective for COVID-19
Lopinavir-ritonavir found ineffective for COVID-19
|
|
gptkbp:principalInvestigator
|
gptkb:Peter_Horby
gptkb:Martin_Landray
|
|
gptkbp:publishedIn
|
gptkb:The_Lancet
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:registration
|
ISRCTN50189673
|
|
gptkbp:sponsor
|
gptkb:University_of_Oxford
|
|
gptkbp:startDate
|
2020
|
|
gptkbp:status
|
ongoing
|
|
gptkbp:trial
|
gptkb:clinical_trial
|
|
gptkbp:website
|
https://www.recoverytrial.net/
|
|
gptkbp:bfsParent
|
gptkb:Martin_Landray
|
|
gptkbp:bfsLayer
|
7
|